More recent studies have shown even higher weight loss and liver fat reductions after treatment with GLP1-RAs in individuals with NAFLD, making these medications a very promising treatment option for NAFLD [39]. The gene discussed is GLP1R; the disease is metabolic dysfunction-associated steatotic liver disease.